Cerevel press release
WebApr 11, 2024 · CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) — Cerevel Therapeutics ( Nasdaq: CERE ), a company dedicated to unraveling the mysteries of the … WebNov 10, 2024 · CAMBRIDGE, Mass., Nov. 10, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics(Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended September 30, 2024 and provided key pipeline and business updates.
Cerevel press release
Did you know?
WebFeb 22, 2024 · Cerevel’s cash, cash equivalents, and marketable securities are expected to continue to support operations into 2025. ... Forward-looking statements in this press … WebMar 21, 2024 · CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, CERE + Free Alerts
WebSep 30, 2024 · Cerevel is conducting two adequately-powered placebo-controlled Phase 2 trials, known as EMPOWER-1 and EMPOWER-2. Data for both trials are expected in the first half of 2024. ... This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to … WebOct 23, 2024 · This release contains forward-looking information about the creation of Cerevel Therapeutics, LLC (“Cerevel”), Pfizer’s equity ownership in Cerevel and Pfizer’s …
WebDec 19, 2024 · CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the …
WebFeb 22, 2024 · CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) — Cerevel Therapeutics, ( Nasdaq: CERE ), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided key pipeline and business updates.
WebApr 11, 2024 · Cerevel Therapeutics announced it will report first quarter 2024 financial results and business updates on Wednesday, May 3, 2024, before the U.S. financial markets open. ... This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to … by the traduzioneWebDec 15, 2024 · CAMBRIDGE, Mass., Dec. 15, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the publication of data from its Phase 1b clinical trial of emraclidine, a novel muscarinic M4 selective positive allosteric … by the tracks bistro knoxvilleWebApr 13, 2024 · “Cerevel continues its track record of innovative deal making with today’s announcement, a strategic funding arrangement to support the completion of the full Phase 3 development program for tavapadon in Parkinson’s disease,” said Tony Coles, chairperson and chief executive officer of Cerevel Therapeutics. ... This press release ... by the tray 盤子工房WebApr 11, 2024 · CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2024 financial results and business updates on Wednesday, May 3, 2024, before the U.S. … cloudberry homeWebMar 31, 2024 · Cerevel will present data demonstrating consistent clinical pharmacology across a wide range of doses of tavapadon in several Phase 1 clinical trials, supporting … cloudberry healthWebApr 11, 2024 · CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics CERE + Free Alerts , a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today... by the trainyardWebJan 3, 2024 · Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. ... This press release contains forward-looking statements that are based on ... cloudberry hyper-v